NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

exwannabe,

This whole response of yours tries to ignore the advantage given by treatment with L when pseudoprogression occurs whether during the course of treatment with L on the treatment arm or with SOC/placebo crossover when no true progression has occurred. Treatment with L during or after chemo/rad pseudoprogression creates a survival advantage that has been duly noted in previous studies.
The only way to properly measure pseudoprogression advantage is to compare each arm to external controls that never had L after SOC induced pseudoprogression. The data retrieved and analyzed from this trial is built around this very issue so that a greater body of evidence could be used to validate the differences.
The only bone you have to pick is with finding out how many SOC pseudoprogressors are in the comparators and I assume that the independent composers of the ECAs did this to the satisfaction of regulators and JAMA Oncology. So you may claim there is bias but there is no proof of bias. I may work under the assumption that SOC induced pseudoprogression occurred in the ECA groups but I have no proof. The fact that both treatment induced and SOC induced pseudoprogression has had such a big impact on this trial, though, leads me to the assumption that it has been accounted for in the ECAs and if I know Dr. Linda Liau very well at all, this issue would not be ignored or allowed to be challenged because of flagrant misappropriation of the data sets; ). Best wishes.